Imprimis Pharmaceuticals Financials

Imprimis Pharmaceuticals Stock Summary

Imprimis Pharmaceuticals competes with Ziff Davis, Grocery Outlet, MYT Netherlands, Cedar Realty, and CDW Corp. Imprimis Pharmaceuticals, Inc., an ophthalmology-focused pharmaceutical company, engages in the development, production, and sale of medications to physicians and patients in the United States. Imprimis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in San Diego, California. Imprimis Pharmaceuticals operates under Drug Manufacturers - Specialty Generic classification in USA and is traded on BATS Exchange. It employs 128 people.

Imprimis Pharmaceuticals Key Financial Ratios

Generally speaking, Imprimis Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Imprimis Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Imprimis Pharmaceuticals over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Imprimis Pharmaceuticals reports annually and quarterly.

Imprimis Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Imprimis Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Imprimis Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Imprimis Pharmaceuticals competition to find correlations between indicators driving Imprimis Pharmaceuticals's intrinsic value. More Info.Imprimis Pharmaceuticals is rated below average in return on equity category among related companies. It is rated below average in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Imprimis Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Imprimis Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Imprimis Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

If you are still planning to invest in Imprimis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Imprimis Pharmaceuticals' history and understand the potential risks before investing.